Neonmind’s NEO-002 synthetic psilocybin applicant will be examined as a very low-dose treatment to regulate and suppress individual appetite. The corporation has secured pharmaceutical quality synthetic psilocybin from Psygen and anticipates initiating a Phase I/II proof-of-concept review for NEO-001 from the around long term. atai is a worldwide biotechnology https://alanz333dyr8.wssblogs.com/profile